Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0013395 (dyspepsia)
 4,879 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Systemic lupus erythematosus (SLE) is an inflammatory connective tissue disease with an autoimmune background, involving various organs and systems during its course. The most important and characteristic clinical manifestations have been included in the revised diagnostic criteria for the classification of SLE published by the American College of Rheumatology (ACR) in 1987. One of them is oral ulceration which occurs in 50% of SLE patients. Oral ulcers and other gastrointestinal complaints such as dyspepsia, abdominal pain and diarrhea, usually attributed to the side-effects of medications, are among the most frequent symptoms in patients with lupus. We report the case of a 42-year-old female suffering from long-standing lupus with kidney and joint involvement, who developed abdominal pain, diarrhea, edema, and cachexia. Our case illustrates the difficulties encountered when searching for the cause of gastrointestinal symptoms. Attention during diagnosis should be given to rare gastrointestinal manifestations of SLE, such as intestinal pseudo-obstruction (IPO) and protein-losing enteropathy (PLE).
 ...
PMID:[Gastrointestinal manifestations of systemic lupus erythematosus. Case report]. 2136 42

Abstract To investigate both the incidence and the dosage used to treat gastrointestinal (GI) symptoms associated with enteric-coated sulfasalazine (Azulfidine EN, AZL) in patients with rheumatoid arthritis (RA), we studied the clinical history of 153 RA patients, and any available data on GI symptoms that might have been associated with AZL. GI symptoms appeared in 64 (42.5%) of the 153 cases. There were 19 events of nausea, vomiting, or dyspepsia, 14 events each of epigastric discomfort and reduction or loss of appetite, 10 events of epigastric, stomach, or abdominal pain, 9 events of heartburn, 8 events of mouth ulcer, 3 events each of loss of taste and abdominal bloating or borborygmus, 2 events each of diarrhea or loose stools, hematemesis or melanemia, and gastric or esophageal ulcer, and 1 event of stomatitis. These results indicate that GI symptoms associated with AZL are usually mild and treatment can continue, with almost all cases responding to a reduction in dose or drug cessation. In some cases, a histamine receptor-2 blocker or proton pump inhibitor is also required.
...
PMID:Gastrointestinal symptoms associated with enteric-coated sulfasalazine (Azulfidine EN tablets). 2438 62